Harrison.ai has petitioned the FDA to exempt some radiology AI devices from premarket review, prompting mixed feedback from industry stakeholders.
Key Details
- 1Harrison.ai seeks FDA exemption for certain computer-aided detection (CAD) AI devices from premarket review.
- 2The company argues current US regulatory pathways are too burdensome for rapidly evolving AI.
- 3Stakeholder comments included feedback from RSNA, ACR, and Patient Alliance for Safe Imaging.
- 4ACR emphasized the need to prioritize patient safety and warned against unintended safety risks.
- 5Harrison.ai has 8 FDA clearances covering 12 indications and its products serve over 1,000 facilities in 40 countries.
- 6Consulting firm Rubrum Advising submitted the petition in October 2023.
Why It Matters
If granted, this exemption could significantly alter the regulatory landscape for radiology AI software, balancing innovation access against patient safety concerns. The decision will set a precedent for future AI device oversight in imaging.
Source
Radiology Business
Related News
•Radiology Business
Navigating Payment and Reimbursement for Radiology AI Solutions
Radiology AI reimbursement in the US remains complex and fragmented, complicating provider and vendor payment strategies.
•HealthExec
Experts Advocate Licensing Model for Clinical AI Regulation
Three prominent medical leaders propose a six-step licensing pathway to govern autonomous clinical AI, drawing direct parallels to physician licensing.
•Radiology Business
AMA Urges Caution on AI for Medical Diagnosis and Treatment
The American Medical Association advises against using AI and chatbots as replacements for physician-led diagnosis and treatment decisions.